Matthew P. Davidsohn

THU-483 BAVENO VII criteria and ANTICIPATE models predict first decompensation in a multi-center U.S. cohort of patients with compensated advanced chronic liver disease (cACLD)

Anahita Rabiee, Christina Lindenmeyer, Atoosa Rabiee, Cyrus Mowdawalla et autres

Response to Ribeiro Jr. et al.

Matthew P. Davidsohn, Divij Verma, Yiyu Zou, Amit Verma et autres

us (code pays fourni par la source)

Cell-free DNA epigenomic profiling enables noninvasive detection and monitoring of translocation renal cell carcinoma

Simon Garinet, Karl Semaan, Jiao Li, Ze Zhang et autres

TFE3 translocation renal cell carcinoma (tRCC), an aggressive kidney cancer driven by TFE3 gene fusions, is frequently misdiagnosed owing to morphologic overlap with other kidney cancer subtypes. Conventional liquid biopsy assays that detect tumor DNA via somatic mutations or copy number alterations …

us (code pays fourni par la source)

Environmental Pollution Triggers Inflammation In Vivo and is Associated With Higher Risk MDS in an Urban Cohort

Megha Verma, Matthew P. Davidsohn, Christopher Maximilian Arends, Divij Verma et autres

us, in (code pays fourni par la source)

Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study

Tanya Jindal, Cindy Y. Jiang, Omar Alhalabi, Matthew P. Davidsohn et autres

• The role of sacituzumab govitecan in the treatment of aUC is unclear after the withdrawal of FDA approval following negative results from TROPiCS-04. • Real-world SG response rate after EV treatment is 18%. • Prior clinical benefit from EV treatment potentially …

us (code pays fourni par la source)

Treatment‐Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study

Amanda Nizam, Charles B. Nguyen, Jinju Li, Emily Craig Zabor et autres

INTRODUCTION: Enfortumab vedotin-ejfv (EV), an antibody-drug conjugate approved for advanced urothelial carcinoma (aUC), has limited real-world safety data and no validated predictive biomarkers. Retrospective studies suggest higher objective response rates (ORR) among patients developing EV-related dermatologic toxicities, but survival implications remain unclear. …

us (code pays fourni par la source)

Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study

Tanya Jindal, Cindy Y. Jiang, Omar Alhalabi, Charles B. Nguyen et autres

us (code pays fourni par la source)

Detection and monitoring of translocation renal cell carcinoma via plasma cell-free epigenomic profiling

Simon Garinet, Karl Semaan, Jiao Li, Ananthan Sadagopan et autres

gene fusions, is frequently misdiagnosed owing to morphologic overlap with other kidney cancer subtypes. Conventional liquid biopsy assays that detect tumor DNA via somatic mutations or copy number alterations are unsuitable for tRCC, since it often lacks recurrent genetic alterations and because …

us (code pays fourni par la source)

PLENARY SESSION 2: IMMUNOLOGY AND MICROENVIRONMENT IN MDS

Aditi Shastri, Megha Verma, Matthew P. Davidsohn, Christopher Maximilian Arends et autres

us (code pays fourni par la source)

Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data

Tanya Jindal, Cindy Y. Jiang, Omar Alhalabi, Amanda Nizam et autres

Enfortumab vedotin (EV) is used as monotherapy or combined with pembrolizumab in advanced urothelial carcinoma (aUC), but biomarker data associated with EV outcomes are limited. We identified 170 patients in the UNITE study who received EV monotherapy and had molecular biomarker data …

us (code pays fourni par la source)

Environmental Pollution Is Associated with Higher Risk MDS in a Diverse Urban Cohort and Triggers Inflammation in a Murine Models

Megha Verma, Matthew P. Davidsohn, Srabani Sahu, Kith Pradhan et autres

Introduction Environmental pollution due to increased industrialization and automobile exhaust has long been associated with adverse effects on human health. While smoking has been associated with clonal hematopoiesis, no studies have comprehensively evaluated the effect of environmental pollutants MDS/myeloid malignancies. Methods A …

us (code pays fourni par la source)

Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS—Meet-URO 26 Real-World Study

Anna Patrikidou, Calogero Saieva, Richard M. Lee‐Ying, Pier Vitale Nuzzo et autres

BACKGROUND: Androgen receptor signalling inhibitors (ARSIs) abiraterone acetate (AA) enzalutamide (Enza), are currently the standard first-line (L1) treatments for metastatic castration-resistant prostate cancer (mCRPC), and docetaxel (D) is reserved as second-line (L2) after ARSI failure. Nonetheless, D use in men ≥ 75 …

fr, it, us, br, ch, au (code pays fourni par la source)